Cancer Immunology, Immunotherapy Q1 Unclaimed
Since its inception in 1976, Cancer Immunology, Immunotherapy (CII) has reported significant advances in the field of tumor immunology. The journal serves as a forum for new concepts and advances in basic, translational, and clinical cancer immunology and immunotherapy. CII is keen to publish broad-ranging ideas and reviews, results which extend or challenge established paradigms, as well as negative studies which fail to reproduce experiments that support current paradigms, and papers that do succeed in reproducing others’ results in different contexts. Cll is especially interested in papers describing clinical trial designs and outcome regardless of whether they met their designated endpoints or not, and particularly those shedding light on immunological mechanisms. CII is affiliated with the Association for Cancer Immunotherapy (CIMT), Canadian Cancer Immunotherapy Consortium (CCIC), The Japanese Association for Cancer Immunology (JACI), Network Italiano per la Bioterapia dei Tumori (NIBIT), and Sociedad Española de Inmunologia-Grupo Española de InmunoTerapia (SEI-GEIT).CIMT: http://www.cimt.eu/homeCCIC: http://www.immunotherapycancer.ca/JACI: http://www.jaci.jp/eng/index.htmlNIBIT: http://www.nibit.org/index.phpSEI-GEIT: http://www.inmunologia.org/grupos/home.php?UpOm5=M&Upfqym5uom=GK CITIM: http://www.canceritim.org
94% of authors who answered a survey reported that they would definitely publish or probably publish in the journal again It has an SJR impact factor of 1,663.
Cancer Immunology, Immunotherapy focuses its scope in these topics and keywords: cells, cell, t, cancer, immune, human, cd, responses, tumor, suppressor, ...
Type: Journal
Type of Copyright:
Languages: English
Open Access Policy: Open Choice
Type of publications:
Publication frecuency: -


3190 €
Inmediate OANPD
Embargoed OA0 €
Non OAMetrics
1,663
SJR Impact factor130
H Index283
Total Docs (Last Year)700
Total Docs (3 years)12270
Total Refs4280
Total Cites (3 years)682
Citable Docs (3 years)5.8
Cites/Doc (2 years)43.36
Ref/DocOther journals with similar parameters
Annual Review of Public Health Q1
Annual Review of Pathology: Mechanisms of Disease Q1
The Lancet Global Health Q1
Annual Review of Clinical Psychology Q1
JAMA - Journal of the American Medical Association Q1
Compare this journals
Aims and Scope
Best articles by citations
Immunological evaluation of patients with hematological malignancies receiving ambulatory cytokine-mediated immunotherapy with recombinant human interferon-a2a and interleukin-2
View moreThe human repertoire of antibody specificities against Thomsen-Friedenreich and Tn-carcinoma-associated antigens as defined by human monoclonal antibodies
View morePostoperative active specific immunization in curatively resected colorectal cancer patients with a virus-modified autologous tumor cell vaccine
View moreImmunological inhibition of carcinogenesis
View moreStructure and function of ETAA16: a novel cell surface antigen in Ewing's tumours
View moreTherapeutic effect of a single peritumoural dose of IL-2 on transplanted murine breast cancer
View moreModulation of costimulation to enhance tumor immunity
View moreEffect of ibuprofen on monocyte activation by liposome-encapsulated muramyl tripeptide phosphatidylethanolamine (CGP 19835A): Can ibuprofen reduce fever and chills without compromising immune stimulation?
View moreThe effect of ranitidine on cellular immunity in patients with multiple myeloma
View moreThe augmentation of lymphokine-activated killer activity following pulsing of human peripheral blood mononuclear cells with recombinant human interleukin-2
View moreGeneration of non-permissive basement membranes by anti-laminin antibody fragments produced by matrix-embedded gene-modified cells
View moreSelective tumoricidal effect of soluble proteoglucan extracted from the basidiomycete, Agaricus blazei Murill, mediated via natural killer cell activation and apoptosis
View moreThe use of a rapid ELISPOT assay to analyze peptide-specific immune responses in carcinoma patients to peptide vs. recombinant poxvirus vaccines
View moreProduction of a human monoclonal antibody recognising a determinant on mouse IgG2b from a patient receiving mouse monoclonal antibody for diagnostic imaging
View moreEffect of picibanil (OK432) on neutrophil-mediated antitumor activity: Implication of monocyte-derived neutrophil-activating factors
View moreGraft-versus-host disease following interleukin-2/lymphokine-activated killer (LAK) cell immunotherapy in a patient with acute myelogenous leukaemia in second complete remission: autologous LAK cells following allogeneic bone marrow transplantation a
View moreAdenoviral-mediated transfer of human wild-type p53, GM-CSF and B7-1 genes results in growth suppression and autologous anti-tumor cytotoxicity of multiple myeloma cells in vitro
View moreSusceptibility of autologous target cells to lysis by lymphokine-activated effectors from interferon-a-treated chronic myelogenous leukaemia patients
View moreEffects of lipopolysaccharide on interleukin-2-induced cytotoxic activity of murine splenocyte cultures: role of prostaglandin E2 and interferons
View moreCommon variable immunodeficiency and malignancy: a report of two cases and possible explanation for the association
View moreTwo-dimensional gel analysis of polypeptides from normal, preneoplastic and neoplastic mouse mammary tissues
View moreThe effects of ?GalCer-induced TCRV?24'V?11+ natural killer T cells on NK cell cytotoxicity in umbilical cord blood
View moreInhibition of interleukin-2 production by tumor cell products and by CKS-17, a synthetic retroviral envelope peptide
View moreTumour escape: antitumour effectors too much of a good thing?
View more
Comments